Status:

COMPLETED

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

Lead Sponsor:

OPKO Health, Inc.

Conditions:

Macular Degeneration

Eligibility:

All Genders

50+ years

Phase:

PHASE2

Brief Summary

The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.

Eligibility Criteria

Inclusion

  • Patients must have subfoveal classic, predominantly classic, or minimally classic lesions, secondary to AMD.
  • Patients must have ETDRS best corrected visual acuity of 64 to 24 letters (20/50 to 20/320 Snellen Equivalent) in the study eye.
  • Patients must be age 50 or older

Exclusion

  • Patients who have received prior treatment with any investigational new drug or device for wet AMD in the study eye within 24 weeks of the screening visit.
  • Patients with advanced glaucoma (greater than 0.8 cup:disk) or intraocular pressure above 22 mmHg in the study eye.
  • Patients with any retinal vasculopathies, including diabetic retinopathy, retinal vein occlusions, etc. in the study eye.
  • Patients with any subfoveal scarring, atrophy, or hemorrhage in the study eye.
  • Patients whose CNV lesion in the study eye contains more than 25% scarring and/or atrophy.
  • Patients who have undergone any extrafoveal/juxtafoveal laser treatment of the study eye within two weeks prior to the screening visit.
  • Patients who received treatment with an investigational drug within 4 weeks prior to the screening visit.

Key Trial Info

Start Date :

July 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2007

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00259753

Start Date

July 1 2005

End Date

December 1 2007

Last Update

August 5 2008

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Acuity Participating Site

Phoenix, Arizona, United States, 85014

2

Retina Centers PC

Tucson, Arizona, United States, 85704

3

Sall Research Medical Center

Artesia, California, United States, 90701

4

Bay Area Retina Associates

Walnut Creek, California, United States, 94598